Antengene's ATG-022 Granted Breakthrough Therapy Designation for the Treatment of Gastric / Gastroesophageal Junction Adenocarcinoma

Antengene Corporation Limited China Hong Kong

Mobile: [phone]

PR Contacts:
Peter Qian
E-mail: [e-mail]
Mobile: [phone]

Logo - https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/antengenes-atg-022-cldn18-2-adc-granted-breakthrough-therapy-designation-for-the-treatment-of-gastricgastroesophageal-junction-adenocarcinoma-302533326.html